Athira Pharma to Participate in Upcoming May Conferences
May 02, 2024 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., May 02, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
April 15, 2024 07:00 ET
|
Athira Pharma, Inc.
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer.
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
April 11, 2024 07:00 ET
|
Athira Pharma, Inc.
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
April 03, 2024 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., April 03, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing novel small molecules to restore neuronal...
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
March 08, 2024 07:00 ET
|
Athira Pharma, Inc.
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s & Parkinson’s Diseases at AD/PD™ 2024
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
February 22, 2024 16:05 ET
|
Athira Pharma, Inc.
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
February 08, 2024 16:02 ET
|
Athira Pharma, Inc.
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
January 08, 2024 07:00 ET
|
Athira Pharma, Inc.
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
January 03, 2024 07:00 ET
|
Athira Pharma, Inc.
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
December 12, 2023 07:00 ET
|
Athira Pharma, Inc.
Exploratory findings add to increasing body of clinical and preclinical data supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neurodegenerative...